TRIAL OF BRYOSTATIN 1 GIVEN AS CONTINUOUS INFUSION IN CANCER PATIENTS

对癌症患者持续输注苔藓抑素 1 的试验

• 批准号: 6114354
• 负责人: Ross C Donehower
• 金额: $ 2.06万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6114354
• 关键词: bioassay; bryostatin; clinical research; clinical trials; drug administration rate /duration; drug screening /evaluation; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; pharmacokinetics

This protocol is to determine the safety and toxicity of bryostatin 1 given as a brief or continuous infusion in cancer patients every 21 days, to evaluate the pharmacokinetcic parameters of byrostatin 1 in this patient population. As no assay exists for this drug, several bioassays will be evaluated in this study. The study is looking for preliminary evidence of therapeutic activity of pharmacokinetic assay of bryostatin 1 activity.

本方案旨在确定苔藓抑素1的安全性和毒性